AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02150434 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Automated oxygen titration
Description: Automated oxygen titration every second to maintain stable SpO2 at a predefined value (94% in the present study)
Study NCT02150434 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Compressed air
Description: compressed air delivered at a fixed flow of 2 L/min
Study NCT02150434 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxygen constant flow
Description: oxygen delivered at a fixed flow of 2L/min
Study NCT01627730 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pretest and posttest scores
Description: pretest and post-test scores are calculated for relative growth scores
Study NCT00272987 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: 80 mg/m2 IV weekly for three weeks
Study NCT00272987 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: trastuzumab
Description: 4 mg/kg loading dose and 2 mg/kg weekly IV
Study NCT00331409 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: 2.5 mg by mouth daily
Study NCT00331409 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: imatinib mesylate
Description: 600 mg by mouth daily
Study NCT00662792 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tiotropium (Tio18GEL)
Description: 18 µg Tiotropium (Tio18GEL) inhalation powder
Study NCT00662792 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Salmeterol MDPI (Salm50DPI)
Description: 50 µg Salmeterol MDPI (Salm50DPI) twice daily (BID)
Study NCT00662792 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tiotropium (T18GEL) + Salmeterol MDPI (S_DPI)
Description: 18 µg Tiotropium (T18GEL) inhalation powder plus 50 µg Salmeterol MDPI (S_DPI) twice daily (BID)
Study NCT00662792 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tiotropium/Salmeterol (T+S_PE)
Description: Fixed-dose combination of 7.5 µg/ 25 µg Tiotropium/Salmeterol (T+S_PE) inhalation powder
Study NCT04196660 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Labor Dance
Description: The pregnant women and their spouses were trained about the labor dance in the prenatal training without disclosing any information regarding the delivery and labor pain. The pregnant women and their spouses/partners who wanted to perform the practice were asked to inform the researcher when the labor started. The researcher stayed with the pregnant women and their spouses during the practice and labor process. The pregnant women started to dance with their spouses during the active phase of the labor process accompanied by meditation music (on a YouTube channel named Ohgertam Jugrefem) in a dim, silent environment. The spouse or partner massaged the pregnant woman's sacral area while dancing. During the active phase of labor, the pregnant women in the DPMG danced with the midwives who were attendant in the delivery room and who were monitoring the pregnant women's status.
Study NCT02681016 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DES Calypso
Description: A standard endovascular procedure is carried out under local anesthesia and under fluoroscopic control. Stenosis of coronary artery is passed by the hydrophilic coronary wire. Then balloon angioplasty of target lesion (if required) is provided. After the angiographic control coronary stent is implanted. After coronary wire removing control angiographic study is provided. Medical therapy includes aspirin(acid acetylsalicylic) 125 - 300 mg/d and plavix(clopidogrel) in dose 300-600 mg prescription before the procedure and heparin (heparin sodium) injection during the procedure(5000 U iv). After the procedure aspirin(acid acetylsalicylic) in dose 100 mg/d within long period should be prescribed in all the patients, and plavix(clopidogrel) in dose 75/d should be prescribed within 12 months.
Study NCT02681016 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: DES Xience Prime
Description: A standard endovascular procedure is carried out under local anesthesia and under fluoroscopic control. Stenosis of coronary artery is passed by the hydrophilic coronary wire. Then balloon angioplasty of target lesion (if required) is provided. After the angiographic control coronary stent is implanted. After coronary wire removing control angiographic study is provided. Medical therapy includes aspirin(acid acetylsalicylic) 125 - 300 mg/d and plavix(clopidogrel) in dose 300-600 mg prescription before the procedure and heparin (heparin sodium) injection during the procedure(5000 U iv). After the procedure aspirin(acid acetylsalicylic) in dose 100 mg/d within long period should be prescribed in all the patients, and plavix(clopidogrel) in dose 75/d should be prescribed within 12 months.
Study NCT02681016 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Coronary angioplasty
Study NCT02681016 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Coronary angioplasty
Study NCT03649399 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Abdominal ultrasound
Description: Abdominal ultrasound for detection of the pancreatic stent
Study NCT04821804 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hyaluronic Acid (HYADENT BG)
Description: the operator topically applied the HYADENT BG on the borders of the graft after stabilization.~on the donor site and injection of HYADENT BG in collagen sponge that was placed over the site, then figure X sutures to close the area using (4-0 polyglycolic acid/ reverse cutting/ 12 mm) resorbable sutures
Study NCT04821804 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Hyaluronic Acid (HYADENT BG)
Description: the operator topically applied the HYADENT BG on the borders of the graft after stabilization.~on the donor site and injection of HYADENT BG in collagen sponge that was placed over the site, then figure X sutures to close the area using (4-0 polyglycolic acid/ reverse cutting/ 12 mm) resorbable sutures
Study NCT01171456 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: Administration of Metformin or placebo prior to conception to prevent the onset of GDM.
Study NCT01171456 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administration of Metformin or placebo prior to conception to prevent the onset of GDM.
Study NCT01913080 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Health Log
Description: The Health Log consists of a permanent booklet and a refillable health log version that is filled out before each doctor's appointment. The permanent booklet has areas to record:~* Personal information and emergency contact(s)~* Physician names and contact information~* Insurance information~* Medications, vitamins and supplements~* Surgeries~* Health history The booklet also includes suggested questions you may want to ask your Rheumatologist about medications, lifestyle, or future/status.~The refillable health log includes questions about pain, fatigue,overall status from the Multi-Dimensional Health Assessment Questionnaire (MDHAQ), and a modified Arthritic Pain and Joint Evaluation. It also has space to write questions for the doctor's visit and prescription refills needed.
Study NCT02028195 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Health check
Description: The program includes four components:~Invitation: All participants receive invitation by mail and a prefixed appointment time. A web-based questionnaire including self-reported health (SF12), physical activity, smoking habits and alcohol use/behaviour has to be answered before Health Examination (HE).~The HE include: Blood pressure, waist, weight, lung function test, lipid profile, HbA1c and fitness (Aastrand).~Health profile pamphlet: The participant receives a pamphlet with the results. The persons are stratified into three groups (I) referral to a consultation in general practice (GP) (II) targeted behavioural programs at the health centre (HC) or (III ) no identified need for health promoting follow-up.~Follow-up according to risk-profile: If referred to GP treatment of risk conditions or diseases will follow national guidelines. The GPs were paid 50 Euros per health interview.
Study NCT01034046 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Low Carbohydrate Diet
Description: Low carbohydrate diet (45% carbohydrate, 35% fat and 20% protein diet) administered utilizing meal replacements.
Study NCT01034046 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Low Fat Diet
Description: Low fat diet (60% carbohydrate, 20% fat and 20% protein diet) administered utilizing meal replacements.
Study NCT02655081 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: high arginine nutritional supplement (Nestle's Impact AR)
Description: Preoperative High-Arginine Nutritional Supplement Prior to Radical Cystectomy
Study NCT03031600 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Radiodilution via Daxor BVA-100
Description: The BVA-100 measures the hematocrit and residual plasma radioactivity of each sample in a semi-automated process, and the residual radioactivity is compared from that of the pre-injection sample to determine plasma volume. The plasma volume and BVA-100-measured hematocrit are then used to calculate the red cell volume and actual blood volume. The BVA-100 is FDA approved for blood volume measurement in vivo, has a reported precision of ± 2.5%, and has demonstrated accuracy and specificity in blood volume assessment in clinical and research settings (Van, P.Y., et al., 2011, Borovka, M., et al., 2013).
Study NCT03031600 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Hemodilution via hematocrit measurement
Description: Hemodilution uses the ideal blood volume and serial hematocrit measures drawn before and after administration of a known quantity of IV fluid to estimate blood volume. Ideal blood volume is calculated using the methods described by Feldschuh and colleagues (Feldschuh, J. and Y. Enson, 1977; Feldschuh, J. and S. Katz, 2007). Hematocrit is measured using the Abbot iSTAT point of care testing device and the lab. Urine output is measured in ml. The ideal blood volume, pre and post-bolus hematocrit, fluid bolus volume, and urine output will be used to calculate estimated blood volume using a mathematical model previously described by the investigators (D'Angelo, M., et al., 2015).
Study NCT04146142 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Transperineal prostate biopsy with or without antibiotic prophylaxis
Description: As described above.
Study NCT04146142 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transperineal prostate biopsy with or without antibiotic prophylaxis
Description: As described above.
Study NCT04613726 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ondansetron
Description: group consisted of receiving IV 8 mg ondansetron diluted in 10 ml of normal saline
Study NCT04613726 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Granisetron
Description: Another comparator group consisted of receivingIV 3 mg granisetron diluted in 10 ml of normal saline
Study NCT04613726 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Control group consisted of patients receiving IV 10 ml normal saline
Study NCT00731172 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: glatiramer acetate
Description: 20 mg daily subcutaneous injection through week 12
Study NCT00731172 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: subcutaneous daiky injection through week 12
Study NCT00062387 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: perifosine
Study NCT05169528 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Colorectal Cancer Prehabilitation Programme
Description: Assessment and Interventions involving the Prehabilitative domains of medical optimisation, exercise prescription, nutrition and mental health optimisation
Study NCT00891579 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pemetrexed (Alimta)
Description: treatment of single pemetrexed with vitamin supplement until discontinued conditions are met
Study NCT00891579 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gefitinib (IRESSA)
Description: treatment of Gefitinib will be applied until discontinued conditions are met
Study NCT03220672 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tailored assessment and educational
Description: Intervention will consist of 45 minutes of anatomy education, pelvic floor assessment and neuromuscular re-education. Women will be given an explanation of how the pelvis is composed, including the viscera and pelvic floor function and anatomy, through a simple explanatory sheet. They will be also informed of the causes of pelvic floor deterioration as well as its consequences.. Neuromuscular re-education will continued by teaching them how to perform slow contractions, fast contractions and lifting contraction. They will be also shown vaginal cones and advised on possible treatment methods if they were needed. After that, women will be given a tip sheet to improve pelvic floor function. Those recommendations will included: Tips to take into account during habits like urination, doing sport, gymnastics or any efforts, pelvic floor muscles exercises and how to use vaginal cones adequately.
Study NCT01243320 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 10ppm Oral Silver Particle
Description: Silver nanoparticles at 10ppm
Study NCT01243320 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 32ppm Oral Silver Particle
Description: Silver nanoparticles at 32ppm
Study NCT04127448 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exergaming Training Group
Description: Training was given using X-box 360 Kinect. Dr. Kawashima's brain and body exercise game comprising of multiple cognitive games out of which 4 selected games were played by the participants. These games were Traffic control (participants have to guide the colored cars into their matching colored tunnels by using their arms), balloon buster (players pop numbered balloons in order from the lowest to the highest), pop till u drop, (match the color that appears on screen with the balloon of same color) and strike a pose (participant have to remember the poses shown and then copy them after few seconds). Games were played for 10 minutes initially then the duration was gradually increased to 30 minutes each session for 3 days/week and duration of 6 weeks. The session included 5-minute warm up, 20-minute interactive gaming, and 5-minute cool down.
Study NCT04127448 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Aerobic Exercise Group
Description: Session of 30-35 minutes, 3 days a week for 6 weeks was given using treadmill (model no TMX58 220). Time and intensity was gradually increased over the duration of 6 weeks. Starting from 10 minutes in 1st week, every 5 minutes was added to aerobics phase to each week until patient reached to 35 minutes in week 6 maintaining the intensity of 40-60% of heart rate reserve (%HRR).
Study NCT01926184 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Affect Regulation Treatment to Enhance Meth Intervention Success (ARTEMIS)
Description: 5-session integrative intervention to improve positive affect as well as boost and extend the effectiveness of contingency management (CM).
Study NCT01926184 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Contingency Management (CM)
Description: 12-week CM protocol that provides escalating monetary reinforcement for biological evidence of methamphetamine abstinence. Delivered as the standard of care for non-treatment-seeking methamphetamine-using MSM in San Francisco. Delivered to both the intervention and attention-control arms
Study NCT01926184 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Contingency Management (CM)
Description: 12-week CM protocol that provides escalating monetary reinforcement for biological evidence of methamphetamine abstinence. Delivered as the standard of care for non-treatment-seeking methamphetamine-using MSM in San Francisco. Delivered to both the intervention and attention-control arms
Study NCT00788346 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Computerized alerts
Description: Computerized Clinical Decision Support to clinician at the time of prescribing
Study NCT00788346 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Alerts Plus Detailing
Description: Computerized Clinical Decision Support to clinician at the time of prescribing PLUS one group academic detailing session
Study NCT02568046 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sym004
Description: Sym004 is a 1:1 mixture of 2 monoclonal antibodies (mAbs), which bind specifically to 2 non-overlapping epitopes of the epidermal growth factor receptor (EGFR).
Study NCT02568046 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFIRI
Description: The standard FOLFIRI regimen consists of Irinotecan (180 mg/m\^2 IV, infused over 60-90 minutes) concurrently with Folinic Acid (400 mg/m\^2 IV, infused over 120 minutes) followed by 5-FU (400 mg/m\^2 IV bolus, then 2400 mg/m\^2 infused over 46 hours).
Study NCT00605787 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tetradecylthioacetic acid (TTA)
Description: 1000mg capsules once daily for 28 days
Study NCT00874939 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-0249 7.5 mg
Description: 4 tablets (1 x 0.5 mg + 2 x 1 mg + 1 x 5 mg) totaling 7.5 mg, single oral dose during each crossover period
Study NCT00874939 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-0249 25 mg
Description: 5 x 5 mg tablets totaling 25 mg, single oral dose during each crossover period
Study NCT00874939 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Donepezil 5mg
Description: One 5 mg tablet, single oral dose during each crossover period
Study NCT03709381 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low Dose Cosyntropin (ACTH) stimulation test
Description: Cosyntropin 1 mcg IV given to subjects at t=0
Study NCT03709381 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High Dose Cosyntropin (ACTH) stimulation test
Description: Cosyntropin 250 mcg IV given to subjects at t=60
Study NCT01675960 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gabapentin
Description: The active drug is in a flavored glycerin based solution. The drug will be given orally or through a gastrointestinal tube. Titration up to a stable dose will take 22 days. The total stable dose is 40mg/kg/day. Once 7 days on this dose are finished, children will take 6 days to reduce their dose and begin their 3 day washout period.
Study NCT01675960 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: The placebo is a glycerin-based clear solution that is flavored similarly to the commercial product. The placebo will be given orally or through a gastrointestinal tube.
Study NCT00874939 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to MK-0249
Description: Five tablets, single oral dose during each crossover period
Study NCT00874939 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to Donepezil
Description: One over-encapsulated capsule, single oral dose during each crossover period
Study NCT03010644 — intervention group
Intervention type: OTHER
Intervention: n/a - observational study
Description: n/a - observational study
Study NCT01313741 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Shoulder arthroplasty with anchor peg glenoid
Description: Shoulder arthroplasty with anchor peg glenoid
Study NCT02452788 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Pharmaceutical care
Description: Pharmacist-provided education on medication adherence in hemodialysis patients.
Study NCT03635658 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: titanium mesh
Description: the non resorbable titanium mesh is used to fix the 1:1 mixture of autograft and xenograft particulate bone on the severely atrophies maxillary ridge.
Study NCT03635658 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: collagen membrane (Sausage technique)
Description: the resorbable collagen membrane is used to fix the 1:1 mixture of autograft and xenograft particulate bone on the severely atrophies maxillary ridge.
Study NCT01589653 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: biphasic insulin aspart 30
Description: Dose individually adjusted by the subjects themselves according to the titration algorithm every second week. Administered subcutaneously (s.c., under the skin) twice daily.
Study NCT01589653 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: biphasic insulin aspart 30
Description: Dose individually adjusted according to the directions given by the investigator. Administered subcutaneously (s.c., under the skin) twice daily.
Study NCT03890042 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dienogest group
Description: VISANNE 2MG Tablet once daily
Study NCT03890042 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gestodene-Ethinyl Estradiol
Description: Gynera tablet once daily
Study NCT03890042 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound
Description: ultrasound assessment of uterine volume
Study NCT03890042 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: visual analogue scale
Description: visual analogue scale for assessment of pain
Study NCT01944852 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Icodextrin
Study NCT01944852 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Icodextrin
Study NCT00918931 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Obatoclax Mesylate
Description: 30 mg given by vein over 3 hours on Days 1-3 of each 14-day study cycle.
Study NCT00299611 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sertraline
Description: Tablets, 50mg each, (1-3TABLETS/DAY) during the Open-label phase for first 8 wks.